Chennai, Aug. 29 -- Highlights

* Targeted, in vivo CRISPR gene therapy is used to stall the progress of triple-negative breast cancer

* Triple-negative breast cancer (TNBC) lacking in estrogen, //progesterone and HER2 receptors is the deadliest of all breast cancers with the highest mortality rates

* This aggressive metastatic cancer has limited treatment options confined to surgery, chemotherapy and radiation

* CRISPR genome editing was used in vivo through an injection into live mice with TNBC

CRISPR gene editing technique can now stop the progression of breast cancer, especially Triple-negative breast cancer (TNBC). CRISPR gene editing is safe in treating pediatric cancers as well, reveals a new study.

Facts About Triple-negative...